NCT03985696: ExoReBLy

Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas

Status unknown NA Last updated 25 July 2022

What this trial tests

NA trial testing blood sample in Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) in 90 participants. Status unknown.

Timeline

2 July 2019

Primary endpoint
2 July 2025

2 July 2025

Quick facts

Lead sponsor	University Hospital, Limoges
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	90
Start date	2 July 2019
Primary completion	2 July 2025
Estimated completion	2 July 2025
Sites	1 location across France

Drugs / interventions tested

• blood sample — full drug profile →

Conditions studied

• Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) — all drugs for Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL) →

Sponsor

University Hospital, Limoges

Who can join

18 and older, any sex, with Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment. Monoclonal anti-CD20 antibody, rituximab, in combination of CHOP chemotherapy (R-CHOP) is widely used with favourable results. Although more than half of patients achieve long-term remission, many are not cured with this immunotherapy. Suboptimal response and/or resistance to rituximab have remained a challenge in the therapy of DLBCL but also of all B-NHL. Exosomes are microvesicles released from tumor B cells that are found in plasma of patients with B-NHL. Exosomes carry therapeutic targets (as CD20, PDL-1) and could act as "decoy-receptors" for immunotherapy. Our objective is to precise, in aggressive B-NHL, the role of exosomes in immunotherapy escape.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Extracellular vesicles in immunomodulation and tumor progression.
   Marar C, Starich B, Wirtz D. · · 2021 · cited 441× · PMID 33753940 · DOI 10.1038/s41590-021-00899-0
2. Exosome-based immunotherapy: a promising approach for cancer treatment.
   Xu Z, Zeng S, Gong Z, Yan Y. · · 2020 · cited 373× · PMID 33183286 · DOI 10.1186/s12943-020-01278-3
3. Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development.
   Kok VC, Yu CC. · · 2020 · cited 318× · PMID 33116515 · DOI 10.2147/ijn.s272378
4. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
   Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
5. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications.
   He G, Peng X, Wei S, Yang S, et al · · 2022 · cited 147× · PMID 35039054 · DOI 10.1186/s12943-021-01440-5
6. Exosomes as Naturally Occurring Vehicles for Delivery of Biopharmaceuticals: Insights from Drug Delivery to Clinical Perspectives.
   Butreddy A, Kommineni N, Dudhipala N. · · 2021 · cited 133× · PMID 34204903 · DOI 10.3390/nano11061481
7. Potential roles of extracellular vesicles in the pathophysiology, diagnosis, and treatment of autoimmune diseases.
   Tian J, Casella G, Zhang Y, Rostami A, et al · · 2020 · cited 66× · PMID 32025210 · DOI 10.7150/ijbs.39629
8. Role of Exosomes for Delivery of Chemotherapeutic Drugs.
   Gebeyehu A, Kommineni N, Meckes DG, Sachdeva MS. · · 2021 · cited 63× · PMID 34375513 · DOI 10.1615/critrevtherdrugcarriersyst.2021036301